SCHEMBL284253

SCHEMBL284253

C=C(C)C(=O)OC.C=C(C)C(=O)OC(C)O

nearest known ligand 0.65

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.65
TSHR P16473 4/20 0.47
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL9567157 0.98 ALDH1A1 (0.62) ALDH1A1TSHRTHRB
SCHEMBL20364 0.91
SCHEMBL10762910 0.91
SCHEMBL27553112 0.91 TSHR (0.48) ALDH1A1TSHRTHRB
SCHEMBL11125870 0.91
Ethylene SCHEMBL8934253 0.89 TSHR (0.46) ALDH1A1TSHRTHRB
Water SCHEMBL10713209 0.89 TSHR (0.46) ALDH1A1TSHRTHRB
SCHEMBL20701419 0.89 TSHR (0.46) ALDH1A1TSHRTHRB
SCHEMBL28133850 0.89 TSHR (0.46) ALDH1A1TSHRTHRB
Acetone SCHEMBL8653588 0.89 TSHR (0.46) ALDH1A1TSHRTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103901722-B Alkaline imaging photosensitive resin composition and preparation method thereof 无锡德贝尔光电材料有限公司 2017-02-22 CN claimed
US-20260061009-A1 METHODS OF TREATING DIABETES USING DEVICES FOR CELLULAR TRANSPLANTATION SERNOVA CORP (CA) 2026-03-05 US disclosed
US-20260021169-A1 CO-TRANSPLANTATION OF MMP-9 ENHANCED MESENCHYMAL STEM CELLS AND PANCREATIC ISLETS FOR THE TREATMENT OF DIABETES UNIV MARYLAND (US) 2026-01-22 US disclosed
US-20230347018-A1 METHODS AND DEVICES FOR CELLULAR TRANSPLANTATION SERNOVA CORP (CA) 2023-11-02 US disclosed
US-11730860-B2 Methods and devices for cellular transplantation SERNOVA CORPORATION (CA) 2023-08-22 US disclosed
US-20220211770-A1 METHODS OF TREATING DIABETES USING DEVICES FOR CELLULAR TRANSPLANTATION SERNOVA CORPORATION (CA) 2022-07-07 US disclosed
EP-3962505-A1 METHODS OF TREATING DIABETES USING DEVICES FOR CELLULAR TRANSPLANTATION Sernova Corporation (CA) 2022-03-09 EP disclosed
WO-2020223670-A1 METHODS OF TREATING DIABETES USING DEVICES FOR CELLULAR TRANSPLANTATION SERNOVA CORPORATION (CA) 2020-11-05 WO disclosed
EP-3290061-B1 METHODS AND DEVICES FOR CELLULAR TRANSPLANTATION SERNOVA CORP (CA) 2020-06-10 EP disclosed
US-20190240375-A1 METHODS AND DEVICES FOR CELLULAR TRANSPLANTATION SERNOVA CORPORATION (CA) 2019-08-08 US disclosed
WO-2007047509-A2 DIFFERENTIATION OF NON-EMBRYONIC STEM CELLS TO CELLS HAVING A PANCREATIC PHENOTYPE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2007-04-26 WO disclosed
US-20060286141-A1 Systems for gel-based medical implants ENDOLUMEN THERAPEUTICS, INC. 2006-12-21 US disclosed
WO-2006086639-A1 VASCULAR/LYMPHATIC ENDOTHELIAL CELLS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2006-08-17 WO disclosed
CN-1809617-A Transfer film for plasma display panel, plasma display panel, and method for producing same JSR CORP (JP) 2006-07-26 CN disclosed
WO-2005058200-A1 SYSTEMS FOR GEL-BASED MEDICAL IMPLANTS ENDOLUMEN THERAPEUTICS, INC. (US) 2005-06-30 WO disclosed
US-5369169-A Polymer blends with enhanced properties ROHM AND HAAS COMPANY (US) 1994-11-29 US disclosed
US-5296537-A Gas barriers ROHM AND HAAS COMPANY (US) 1994-03-22 US disclosed
US-5208083-A (meth)acrylate and/or glutarimide containing polymer mixed with vinyl alcohol polymer; oxygen barrier; containers ROHM AND HAAS COMPANY (US) 1993-05-04 US disclosed
US-5147930-A Vapor barriers; blends of alkyl (meth)acrylate and/or glutarimide polymers with vinyl alcohol polymers ROHM AND HAAS COMPANY (US) 1992-09-15 US disclosed
EP-0373911-A1 Polymer blends with enhanced properties ROHM AND HAAS COMPANY (US) 1990-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021169-A1 CO-TRANSPLANTATION OF MMP-9 ENHANCED MESENCHYMAL STEM CELLS AND PANCREATIC ISLETS FOR THE TREATMENT OF DIABETES MMP9, MMP1, IAPP ALDH1A1 710/4885TSHR 2764/4885THRB 2594/4885
US-20260061009-A1 METHODS OF TREATING DIABETES USING DEVICES FOR CELLULAR TRANSPLANTATION IAPP, PGF, INSR ALDH1A1 3557/4885TSHR 1498/4885THRB 1661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.